Trial Profile
Direct Acting Antiviral Agent (DAA) Therapy Is Safe and Efficacious in Pediatric Patients With Chronic Hepatitis C: Real World Data From the Public Health Perspective
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2021
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ledipasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 04 Apr 2018 New trial record